Patents Assigned to UCP GEN-Pharma AG
  • Publication number: 20020142414
    Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.
    Type: Application
    Filed: January 22, 2001
    Publication date: October 3, 2002
    Applicant: UCP Gen-Pharma AG
    Inventors: Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, Francois Meyer, Ursula Seemuller, Hans Fritz, Walter Marki, Sefik Alkan
  • Patent number: 6436901
    Abstract: The present invention provides a freeze dried pharmaceutical composition comprising hirudin, potassium phosphate and a sugar.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: August 20, 2002
    Assignees: UCP Gen-Pharma AG, Novartis Corporation
    Inventor: Tudor Arvinte
  • Patent number: 6342373
    Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: January 29, 2002
    Assignee: UCP GEN-Pharma AG
    Inventors: Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, Francois Meyer, Ursula Seemüller, Hans Fritz, Walter Märki, Sefik Alkan
  • Patent number: 6103515
    Abstract: A novel process for the production of heterologous proteins including the use of certain transformed protease deficient yeast strains is provided. The invention concerns also said transformed yeast strains and methods for the production thereof.
    Type: Grant
    Filed: June 8, 1992
    Date of Patent: August 15, 2000
    Assignees: Novartis Corporation, UCP Gen-Pharma AG
    Inventors: Hansjorg Treichler, Kenji Takabayashi, Dieter Heinrich Wolf, Jutta Heim
  • Patent number: 5972698
    Abstract: The present invention relates to novel inhibitors of human tryptase, to their isolation from leeches, to nucleotide sequences encoding the novel inhibtor molecules or fragments thereof, to vectors containing the coding sequence thereof, to host cells transformed with such vectors, to the recombinant production of the inibitors, to pharmaceutical compositions containing the novel inhibitor molecules, and to their use in diagnosis and therapy.
    Type: Grant
    Filed: January 25, 1996
    Date of Patent: October 26, 1999
    Assignees: Novartis Corporation, UCP Gen-Pharma AG
    Inventors: Hans Fritz, Christian Sommerhoff
  • Patent number: 5422249
    Abstract: The invention relates to DNA sequences that code for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors containing such DNA sequences, host cells transformed with such hybrid vectors, novel polypeptides with thrombin-inhibiting activity produced from such transformed host cells, processes for the manufacture of these DNA sequences, hybrid vectors and transformed host cells, and processes for the manufacture of these thrombin-inhibitors using the transformed host cells. The hirudin compounds that can be produced according to the invention have valuable pharmacological properties.
    Type: Grant
    Filed: September 15, 1993
    Date of Patent: June 6, 1995
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AG
    Inventors: Manfred Liersch, Hans Rink, Walter Marki, Markus G. Grutter, Bernd Meyhack
  • Patent number: 5268296
    Abstract: Novel polypeptides, designated hirullins, have a strong antithrombic activity and can therefore be used for the therapy and prophylaxis of thromboses. Said compounds are isolated from the leech Hirudinaria manillensis or are produced by conventional peptide synthesis or by recombinant DNA techniques. DNA sequences encoding hirullins P6 and P18 are supplied, hybrid vectors and transformed microorganisms for recombinant hirullin production are supplied.
    Type: Grant
    Filed: February 21, 1992
    Date of Patent: December 7, 1993
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AG
    Inventors: Reinhard Maschler, Verena Steiner, Markus G. Grutter
  • Patent number: 5180667
    Abstract: DNA encoding novel eglin mutants that differ from the natural eglins B and C by the replacement of amino acids in the region of the active center (amino acid 45) by other amino acids are provided. The mutants, which are produced by recombinant genetic engineering, have valuable pharmacological properties.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: January 19, 1993
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AG
    Inventors: Markus G. Grutter, Dirk Heinz, Manfred Liersch
  • Patent number: 5126134
    Abstract: There is provided a pharmaceutical composition comprising as component A a plasminogen activator and as component B hirudin together with a pharmaceutically acceptable carrier. The pharmaceutical composition can be used for the prophylaxis and therapy of thrombosis or diseases caused by thrombosis.
    Type: Grant
    Filed: September 18, 1989
    Date of Patent: June 30, 1992
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AG
    Inventors: Jutta Heim, Giancarlo Agnelli, Czeslaw Czendlik
  • Patent number: 5114922
    Abstract: Novel polypeptides, designated hirullins, have a strong antithrombic activity and can therefore be used for the therapy and prophylaxis of thromboses. Said compounds are isolated from the leech Hirudinaria manillensis or are produced by conventional peptide synthesis or by recombinant DNA techniques.
    Type: Grant
    Filed: June 8, 1989
    Date of Patent: May 19, 1992
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AG
    Inventors: Reinhard Maschler, Verena Steiner, Markus G. Grutter, Fritz Raschdorf